Similar articles

• Synergistic activities of antituberculous drugs with cerulenin and trans-cinnamic acid against Mycobacterium tuberculosis.

  Rastogi N, Goh KS, Horgen L, Barrow WW. Rastogi N, et al. FEMS Immunol Med Microbiol. 1998 Jun;21(2):149-57. doi: 10.1111/j.1574-695X.1998.tb01161.x. FEMS Immunol Med Microbiol. 1998. PMID: 9685005
• The genetics of multiple drug resistance in Mycobacterium tuberculosis and the Mycobacterium avium complex.

  Morris SL, Rouse DA. Morris SL, et al. Res Microbiol. 1996 Jan-Feb;147(1-2):68-73. doi: 10.1016/0923-2508(96)80206-3. Res Microbiol. 1996. PMID: 8761725 Review. No abstract available.
• Ribosomal drug resistance in mycobacteria.

  Sander P, Meier A, Böttger EC. Sander P, et al. Res Microbiol. 1996 Jan-Feb;147(1-2):59-67. doi: 10.1016/0923-2508(96)80205-1. Res Microbiol. 1996. PMID: 8761724 Review. No abstract available.
• Prospects for development of new antimycobacterial drugs.

  Tomioka H. Tomioka H. J Infect Chemother. 2000 Mar;6(1):8-20. doi: 10.1007/s101560050043. J Infect Chemother. 2000. PMID: 11810525 Review.
• New rifabutin analogs: synthesis and biological activity against Mycobacterium tuberculosis.

  Barluenga J, Aznar F, García AB, Cabal MP, Palacios JJ, Menéndez MA. Barluenga J, et al. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5717-22. doi: 10.1016/j.bmcl.2006.08.090. Epub 2006 Sep 20. Bioorg Med Chem Lett. 2006. PMID: 16987658